Current Cardiology Reports

, Volume 14, Issue 4, pp 433–442

Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in Atherosclerosis Prevention

Authors

    • Division of Cardiovascular Medicine, Lillehei Heart InstituteUniversity of Minnesota Medical Center
  • Gary S. Francis
    • Division of Cardiovascular Medicine, Lillehei Heart InstituteUniversity of Minnesota Medical Center
Ischemic Heart Disease (S Brener, Section Editor)

DOI: 10.1007/s11886-012-0275-9

Cite this article as:
Patarroyo Aponte, M.M. & Francis, G.S. Curr Cardiol Rep (2012) 14: 433. doi:10.1007/s11886-012-0275-9

Abstract

Atherosclerosis is a highly complex biological process that has become the scourge of modern civilization. Endothelial dysfunction is the first step in the development of atherosclerosis. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the development of endothelial dysfunction and atherosclerosis. Several studies have shown that in vitro blockade of the RAAS is associated with improvement in markers of endothelial dysfunction and inflammation. Many clinical trials have demonstrated a clear benefit of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) manifested by a reduction of cardiovascular events. These findings suggest that ACEIs and ARBs can play an important role in prevention of atherosclerosis and in the delay of its progression. In this review we focus on the importance of RAAS blockade to prevent or delay progression of atherosclerosis and its impact on reduction of cardiovascular events.

Keywords

AtherosclerosisRenin-angiotensin-aldosterone-systemAngiotensin-converting enzyme inhibitorsAngiotensin receptor blockersPrevention

Copyright information

© Springer Science+Business Media, LLC 2012